On December 25th, the 8th Zhongguancun International Frontier Technology Competition in the biomedical field concluded successfully at the Dongsheng International Science Park in Zhongguancun. After i

Recently, the "6th China Biomedical Industry Innovation and Transformation Forum and the 1st Guangdong-Hong Kong-Macao Greater Bay Area Biomedical Industry Innovation and Transformation Forum" was gra

Genecradle Therapeutics' independently developed GC101 injection was officially included in the list of breakthrough therapy varieties. The indication is for Type 2 spinal muscular atrophy (5q SMA)

Recently, the 9th "Maker China" Beijing Small and Medium Enterprises Innovation and Entrepreneurship Competition, also known as "Maker Beijing 2024," concluded successfully. In this prestigious event,

November 14, 2024, saw the acceptance for review by the National Medical Products Administration of another new product developed by Genecradle Therapeutics—GC310 adeno-associated virus (AAV) injectio

From November 4th to 6th, 2024, a delegation from Beijing Genecradle Therapeutics Technology Co., Ltd. traveled to Stockholm, Sweden, to attend the highly anticipated 2024 BIO-Europe Autumn Conference.

On October 18, 2024, Secretary Zhang Qiang of the Working Committee of Beijing E-Town visited Beijing Genecradle Therapeutics Technology Co., Ltd. (hereinafter referred to as "Genecradle Therapeutics"

A phase I clinical trial titled "Evaluation of the Safety and Tolerability of GC304 Adeno-Associated Virus Injection in Patients with Primary Hypertriglyceridemia and a History of Acute Pancreatitis"

Professor Wu Xiaobing Invited to the China Women Physicians Conference and Elected as a Member of the Rare Disease Professional Committee